PMDA posts package insert revisions for drugs based on revision consultations
添付文書改訂相談に基づく添付文書改訂（医薬品）を掲載しました
Published: 2026-08-19 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Medium · First detected by this dashboard: 2026-08-20
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
The Pharmaceuticals and Medical Devices Agency (PMDA) safety updates page lists a new announcement, dated 2026-08-19, that it has posted package insert (prescribing information) revisions for pharmaceutical products made on the basis of package insert revision consultations. The provided metadata does not identify which drugs or which revisions are involved.
Business Impact
Manufacturers, marketing authorization holders, and healthcare-related businesses handling the affected drugs may need to check whether any posted revisions relate to their products. The scope of any impact cannot be determined from the metadata provided.
Recommended Action
Review the official Japanese PMDA page to identify which drug package inserts were revised and to confirm the details and applicability.